Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2024-03-05 eCollection Date: 2024-01-01 DOI:10.1177/11795549241228232

Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai

{"title":"Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma.","authors":"Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai","doi":"10.1177/11795549241228232","DOIUrl":null,"url":null,"abstract":"Background: The risk of first recurrence of hepatocellular carcinoma (HCC) within years 5 to 10 after curative hepatectomy remains unknown. We aimed to assess the incidence and prognostic factors for very late recurrence among patients who achieved 5 years' recurrence-free survival (RFS) after primary resection.Methods: We retrospectively analyzed 337 patients with early-stage HCC underwent primary tumor resection and achieved more than 5 years' RFS.Results: A total of 77 patients (22.8%) developed very late recurrence. The cumulative very late recurrence rate increased from 6.9% and 11.7% to 16.6% at 6, 7, and 8 years, respectively. Patients stopped smoking had a higher rate of very late RFS.Conclusions: The high rates of very late recurrence in HCC indicate that patients warrant continued surveillance, even after 5 recurrence-free years. Moreover, smoking is a risk factor for very late HCC recurrence, and quitting smoking may reduce the risk of very late recurrence.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"18 ","pages":"11795549241228232"},"PeriodicalIF":1.9000,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916494/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549241228232","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The risk of first recurrence of hepatocellular carcinoma (HCC) within years 5 to 10 after curative hepatectomy remains unknown. We aimed to assess the incidence and prognostic factors for very late recurrence among patients who achieved 5 years' recurrence-free survival (RFS) after primary resection.

Methods: We retrospectively analyzed 337 patients with early-stage HCC underwent primary tumor resection and achieved more than 5 years' RFS.

Results: A total of 77 patients (22.8%) developed very late recurrence. The cumulative very late recurrence rate increased from 6.9% and 11.7% to 16.6% at 6, 7, and 8 years, respectively. Patients stopped smoking had a higher rate of very late RFS.

Conclusions: The high rates of very late recurrence in HCC indicate that patients warrant continued surveillance, even after 5 recurrence-free years. Moreover, smoking is a risk factor for very late HCC recurrence, and quitting smoking may reduce the risk of very late recurrence.

查看原文本刊更多论文

吸烟是手术切除的早期原发性肝细胞癌晚期复发的风险因素。

背景：肝细胞癌（HCC）治愈性肝切除术后5至10年内首次复发的风险仍然未知。我们的目的是评估原发性切除术后获得 5 年无复发生存期（RFS）的患者中极晚期复发的发生率和预后因素：我们回顾性分析了 337 例接受原发肿瘤切除术并获得 5 年以上无复发生存期的早期 HCC 患者：结果：共有 77 例患者（22.8%）出现晚期复发。6年、7年和8年的累积晚期复发率分别从6.9%和11.7%上升至16.6%。戒烟患者的极晚期复发率更高：结论：HCC 的极晚期复发率很高，这表明即使在 5 年无复发后，患者仍需继续接受监测。此外，吸烟是 HCC 极晚期复发的一个风险因素，戒烟可降低极晚期复发的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.